Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)~* Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory~* Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma~* Evidence of at least one measurable lesion as detected by radiological or photographic methods~* Adequate bone marrow, organ function, cardiac and laboratory parameters~* Normal functioning of daily living activities~Exclusion Criteria:~* Any untreated CNS metastases~* Uveal or mucosal melanoma~* History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO~* Patients with washout period \< 6 weeks from the last dose of ipilimumab or other immunotherapy.~* Previous systemic chemotherapy for unresectable locally advanced or metastatic melanoma.~* History of Gilbert's syndrome~* Prior therapy with a MEK- inhibitor~* Impaired cardiovascular function or clinically significant cardiovascular diseases~* Uncontrolled arterial hypertension despite medical treatment~* HIV positive or active Hepatitis A or B~* Impairment of gastrointestinal function~* Patients who have undergone major surgery or radiotherapy ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;~* Patients with neuromuscular disorders that are associated with elevated CK.~* Pregnant or nursing (lactating) women~* Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEK162 (Type: EXPERIMENTAL): None
- Dacarbazine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).